( NASDAQ-NMS:CRIS )

News from the debiopharm group A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages.

Latest

Jan 13, 2014, 11:30 ET Debiopharm Group Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...


Jan 08, 2014, 03:00 ET Spinomix Announces a Milestone Payment from Debiopharm Group™and the Appointment of a new CEO

Spinomix SA, a Swiss company advancing molecular diagnostic through innovative sample preparation technologies and Debiopharm...


Oct 24, 2013, 11:00 ET Atheris and Debiopharm Group™ to Collaborate for the Lead Optimization of Debio 0826 Using a "Reverse-Discovery" Strategy

Atheris Laboratories, a world leading company in venom-based drug discovery and lead optimization, and Debiopharm Group™ (Debiopharm), a...


Oct 22, 2013, 08:25 ET Curis and Debiopharm Group™ Announce Initiation of Phase I Dose Finding Clinical Study with a Combination of HSP90 Inhibitor Debio 0932 and Everolimus (Afinitor®)

Curis, Inc. (NASDAQ: CRIS), an oncology focused company developing novel, targeted drug candidates for the treatment of human cancers, and...


Oct 07, 2013, 03:00 ET Experimental Therapeutics Centre and Debiopharm Group™ to Collaborate for the Development of an Epigenetic Innovative Oncology Target

The Agency for Science, Technology and Research (A*STAR)'s Experimental Therapeutics Centre (ETC), a center of excellence to advance and...


Oct 04, 2013, 04:00 ET Presented by the Japanese Cancer Association and Debiopharm Group™ The 'JCA Mauvernay Award 2013' goes to Doctors Kitabayashi and Yano

Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that...


Sep 09, 2013, 09:35 ET Debiopharm Group and TCG Lifesciences Ltd. Enter into an Exclusive Research Agreement to Develop a Novel Class of Antibiotics, a New Strategic Therapeutic Area for Debiopharm

Debiopharm Group (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target...


Sep 05, 2013, 03:00 ET Go To Market Consulting Inc. and Debiopharm Group Collaborate to Identify Early Stage In-licensing Opportunities on the US West Coast

Go To Market Consulting Inc. (Go To Market), a San Francisco headquartered business development representation and marketing services life...


Sep 02, 2013, 03:00 ET Debiopharm Group™ Initiates Phase I Dose Escalation Study With Debio 1347 (CH5183284) in Advanced Solid Tumors with FGFR Alterations

Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that...


Aug 29, 2013, 03:00 ET Debiopharm Group™ Presents the 'Debiopharm Group Life Sciences Award 2013' and two 'Junior Debiopharm Group Life Sciences Awards 2013' During the Annual EPFL SV- Life Science Symposium

Debiopharm Group™ (Debiopharm), the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs...


Jul 04, 2013, 03:00 ET Quartz Bio SA Supports Debiopharm Group Precision Medicine Bioinformatics

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...


Jun 19, 2013, 03:46 ET Aurigene and Debiopharm Group™ Report Nomination of Development Candidate Debio 0617B in Oncology

Aurigene Discovery Technologies, a Bangalore-based biotech focusing on small molecule and peptide drug discovery and Debiopharm Group™...


Jun 07, 2013, 03:00 ET Diagnoplex S.A. Closes a Financing Round led by Debiopharm Group™

Diagnoplex SA, a developer of molecular diagnostics for colon cancer and Debiopharm Diagnostics SA, part of the Swiss-based global...


Jun 04, 2013, 04:00 ET Debiopharm Group™ Announces Additional Phase I Clinical Trial Evaluating Debio 1143 Combined With Chemotherapies for Patients With Selected Solid Malignancies

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of...


May 23, 2013, 03:00 ET Cenix BioScience and Debiopharm Group Collaborate to Identify Predictive Biomarkers

Cenix BioScience, a leading preclinical contract research provider and technology developer specialized in RNAi-, miRNA- and high content-driven...


Apr 24, 2013, 03:00 ET Oncotest GmbH and Debiopharm Group Announce a Successful Partnership in the Identification of Biomarker Candidates

Oncotest GmbH and Debiopharm Group™ (Debiopharm) a Swiss-based global biopharmaceutical group, are pleased to announce the successful...


Apr 18, 2013, 03:00 ET Debiopharm Group to Support Ascepion in the Development of Debio 1144 for the Treatment of Chinese Cancer Patients

Suzhou Ascepion Pharmaceuticals, Inc. (Ascepion), a Chinese leading biotech company focusing on the discovery and development of world-class...


Jan 08, 2013, 01:00 ET Chugai and Debiopharm Group Announce an Exclusive License Agreement for Anti-Cancer Agent, FF284 (Debio 1347)

Chugai Pharmaceutical Co., Ltd. ("Chugai") and Debiopharm GroupTM ("Debiopharm") announced today that on December 17, 2012, they entered into a...


Dec 07, 2012, 03:00 ET Dr. Reddy's Launches Debiopharm's Pamorelin® LA in India for the Treatment of Locally Advanced or Metastatic, Hormone-Dependent Prostate Cancer

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...


Sep 21, 2012, 03:00 ET The Japanese Cancer Association and Debiopharm Group Present Doctors Oshima and Tanaka with the 2012 'JCA-Mauvernay Award' for their Innovative and Outstanding Cancer Research

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...


Aug 27, 2012, 03:00 ET Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...


Jun 18, 2012, 03:00 ET Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases

Debiopharm Group™ (Debiopharm), a global biopharmaceutical development group that focuses on serious medical conditions and...


Jun 06, 2012, 04:00 ET Debiopharm Presented Results at the ASCO 2012 Annual Meeting - Results of Phase I Study With Debio 0932, an Oral HSP90 Inhibitor in Patients With Solid Tumours

Debiopharm Group™ (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription...


May 15, 2012, 03:00 ET Debiopharm and Vifor Pharma Sign an Exclusive Agreement for the Distribution and Commercialization of Pamorelin®LA in Switzerland - A Drug Treatment for Prostate Cancer and Endometriosis

Debiopharm Group™ (Debiopharm) and Vifor Pharma announce the signing of an exclusive agreement covering the distribution and...


Feb 16, 2012, 07:00 ET Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932

Curis, Inc. (NASDAQ: CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, and Debiopharm...